Hims & Hers' Sales Grow 49%, But Margins Shrink And Its Earnings Outlook Falls
Product and service costs took a bigger share of sales, while quarterly free cash flow fell to $26.0 million from $79.4 million.
Hims & Hers Health, which connects customers online with healthcare providers for prescription treatments, cut its forecast for full-year adjusted earnings Monday even as third-quarter sales grew 49% to $890.4 million. Results released with its SEC filing showed gross margin falling to 57% from 74% a year earlier and a $33.0 million net loss replacing a $15.8 million profit.
More Sales, Less Left Over
Hims & Hers generated $599.0 million in sales a year earlier. But product and service costs climbed to $381.2 million from $156.9 million, leaving gross profit of $509.2 million against $442.1 million.
Operating expenses reached $575.3 million, compared with $430.3 million. General and administrative spending rose to $151.5 million from $80.7 million, while technology and development spending increased to $69.4 million from $40.6 million.
The company lost $66.1 million from operations, versus an $11.8 million operating profit a year earlier. Its net loss amounted to $0.14 per share.
Adjusted EBITDA—earnings excluding interest, taxes, depreciation, stock-based pay and other specified items—was $82.4 million, compared with $78.4 million. That measure accounted for 9% of sales, down from 13%.
International Growth Outpaces U.S. Sales
Outside the United States, revenue rose 321% to $233.3 million. U.S. revenue increased 21% to $657.1 million. Subscribers reached 2.788 million, a 13% increase, while monthly revenue per average subscriber rose 30%, from $81.00 to $105.00.
Customers use the company's websites and apps to obtain care for conditions including hair loss, sexual health, weight loss and mental health. Many offerings carry recurring subscription charges, and the company's own pharmacies fill most prescriptions. Its platform serves the United States, Canada, the United Kingdom and European Union markets.
The U.S. weight-loss business changed direction in the first quarter toward branded GLP-1 medications, with compounded versions offered on a limited scale. Inventory write-downs, third-party expenses and employee compensation charges followed, with further restructuring costs in the second and third quarters.
Hims & Hers excludes those charges from adjusted EBITDA. This quarter it also changed the measure to exclude foreign-currency gains and losses because of its international expansion. Quarterly adjustments included $64.5 million of stock-based pay, $35.4 million of acquisition, transaction and investment earn-out costs, and $3.8 million of restructuring expenses.
Cash Falls As Expansion Looms
Operations generated $65.4 million in cash, compared with $148.7 million a year earlier. Free cash flow, which subtracts capital investment from operating cash, fell to $26.0 million from $79.4 million.
Hims & Hers Chief Financial Officer Yemi Okupe said the company was “intentionally pacing marketing spend ahead of several planned expansions to our platform in the fourth quarter.” Marketing expenses were $247.3 million, versus $232.2 million.
Management narrowed its full-year revenue outlook to $3.13 billion–$3.15 billion and reduced its adjusted EBITDA forecast to $257 million–$277 million. It expects that adjusted measure to equal 8%–9% of annual revenue.
For the fourth quarter, Hims & Hers expects sales of $875 million–$895 million and adjusted EBITDA of $70 million–$90 million, or 8%–10% of sales.
Sources
- 8-K Filing — Hims & Hers Health, Inc. (HIMS) — SEC EDGAR
- Exhibit hims-20260930x8xkearningsr.htm — Hims & Hers Health, Inc. 8-K exhibit — SEC EDGAR
- Hims & Hers Stock Slips Further as Q3 Print Disappoints — benzinga.com
- Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results — businesswire.com